These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 24713245)
41. Cystic hypersecretory carcinoma with invasion: Case series on a rare variant of carcinoma breast. Yami H; Thambi R; Priya PV; Sundaram S Indian J Pathol Microbiol; 2022; 65(1):149-151. PubMed ID: 35074982 [TBL] [Abstract][Full Text] [Related]
42. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
43. [Clinicopathologic study of breast cancer with features of endocrine ductal carcinoma-in-situ]. Yang WT; Xu YX; Zhang TQ Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):594-7. PubMed ID: 17134566 [TBL] [Abstract][Full Text] [Related]
44. [Clinicopathological features of the mucocele-like lesions in the breast]. Ding HY; Yang GZ Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):31-4. PubMed ID: 18509982 [TBL] [Abstract][Full Text] [Related]
45. [Clinicopathologic features and immunohistochemistry of the basal-like subtype of invasive breast carcinoma]. Liu LP; Bai J; Wei Y; Qi XD; Si TC; Li W; Pan H Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):101-5. PubMed ID: 23710916 [TBL] [Abstract][Full Text] [Related]
46. Mucinous cystadenocarcinoma of the breast coexisting with infiltrating ductal carcinoma. Chen WY; Chen CS; Chen HC; Hung YJ; Chu JS Pathol Int; 2004 Oct; 54(10):781-6. PubMed ID: 15482568 [TBL] [Abstract][Full Text] [Related]
47. [Expression of vacuole membrane protein 1 and its prognostic value in invasive ductal carcinoma of the breast]. Liu F; Niu Y; Liu N; Zhang W; Wang SL; Liu H; Zhang TX Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):86-9. PubMed ID: 23710913 [TBL] [Abstract][Full Text] [Related]
48. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions. Liu TT; Li XF; Wang L; Yang JL Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595 [TBL] [Abstract][Full Text] [Related]
49. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
50. [Pathological study of radial sclerosing lesions]. Zhang XL; Yang GZ; Ding HY Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):10-3. PubMed ID: 20388392 [TBL] [Abstract][Full Text] [Related]
51. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. Grin A; O'Malley FP; Mulligan AM Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450 [TBL] [Abstract][Full Text] [Related]
52. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Dabbs DJ; Chivukula M; Carter G; Bhargava R Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011 [TBL] [Abstract][Full Text] [Related]
53. Sonographic findings in a patient with cystic hypersecretory duct carcinoma of the breast. Park C; Jung JI; Lee AW; Cheon HM; Hahn ST; Lee JM J Clin Ultrasound; 2004 Jan; 32(1):29-32. PubMed ID: 14705175 [TBL] [Abstract][Full Text] [Related]
54. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma. Zheng WQ; Looi LM; Cheah PL Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929 [TBL] [Abstract][Full Text] [Related]
55. Invasive cystic hypersecretory carcinoma of the breast: a case report. Liu J; Yang W; Wu X; Hu X Int J Clin Exp Pathol; 2015; 8(6):7499-502. PubMed ID: 26261660 [TBL] [Abstract][Full Text] [Related]
56. Stereotaxic fine needle aspiration cytology of clinically occult malignant and premalignant breast lesions. Bibbo M; Scheiber M; Cajulis R; Keebler CM; Wied GL; Dowlatshahi K Acta Cytol; 1988; 32(2):193-201. PubMed ID: 2831687 [TBL] [Abstract][Full Text] [Related]
57. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor. Xu S; Wei B; Zhang H; Qing M; Bu H Oncol Rep; 2008 Jun; 19(6):1469-75. PubMed ID: 18497952 [TBL] [Abstract][Full Text] [Related]
58. Invasive cystic hypersecretory carcinoma of the breast. Chitti S; Misra S; Ahuja A; Gupta N; Yelamanchi R Autops Case Rep; 2022; 12():e2021375. PubMed ID: 35574044 [TBL] [Abstract][Full Text] [Related]
59. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005 [TBL] [Abstract][Full Text] [Related]
60. [Expression and significance of hTERT mRNA in breast carcinoma and its relation to p53]. Tang F; Gu DH; Wang H; Zhu TF; Zhu HG; Xu ZD; Hu XQ Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):192-5. PubMed ID: 16875603 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]